Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Search
Our Retinal Health Partnering Interests
Our Retinal Health Partnering Interests
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
CIA Reporting Requirements
CIA Reporting Requirements
Corporate Profile
Corporate Profile
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US
Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.
Fornovo San Giovanni (Bidachem)
Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health
Partnering Interests
Partnering Interests
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Trends & Insights
News
Ruminants
Ruminants
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
History
History
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
The Research Process
The Research Process
Vision & Values
Vision & Values
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund